Luvira V, Kamsa-ard S, Kamsa-ard S, Luvira V, Srisuk T, Pugkhem A, Pairojkul C, Bhudhisawasdi V

Language: English
References: 25
Page: 802-809
PDF size: 265.42 Kb.

ABSTRACT

Introduction and aim. The carcinogenesis of tubular and papillary cholangiocarcinoma (CCA) differ. The available epidemiologic studies about risk factors for CCA do not differentiate between the tubular and papillary type. The current study investigated the relationship between the number of repeated use of Praziquantel (PZQ) treatments and each type of CCA. Material and methods. This was a hospital-based, matched, case-control study of patients admitted to Srinagarind Hospital, Khon Kaen University. The patients were 210 pathologically-confirmed cases of CCA, while the controls were 840 subjects diagnosed with other diseases. The 4 controls were individually matched with each case by sex, age, and date of admission. The cases were classified according to location (intrahepatic vs. extrahepatic) and cell type (papillary vs. tubular). Multivariable conditional logistic regression was used for the analysis. Results. After adjusting for confounders, there were statistically significant associations between intrahepatic and papillary CCA and repeated use of PZQ treatment. The respective odds of developing intrahepatic CCA for those who used PZQ once, twice, or more was 1.54 (95%CI:0.92-2.55 ), 2.28 (95%CI:0.91-5.73), and 4.21 (95%CI:1.61-11.05). The respective odds of developing papillary CCA for those who used PZQ once, twice, or more was 1.45 (95%CI:0.80-2.63), 2.96 (95%CI:1.06-8.24), and 3.24 (95%CI:1.09-9.66). There was no association between number of uses of PZQ treatment and developing extrahepatic or tubular CCA. Conclusion. The current study found an association between papillary and intrahepatic CCA and repeated use of PZQ treatment. We suggest further study on the risk factors for papillary and tubular CCA should be performed separately.

REFERENCES

1. Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol 2015; 29: 221-32.

2. Augustine MM, Fong Y. Epidemiology and Risk Factors of Biliary Tract and Primary Liver Tumors. Surg Oncol Clin North Am 2014; 23: 171-88.

3. Andrews RH, Sithithaworn P, Petney TN. Opisthorchis viverrini: an underestimated parasite in world health. Trends in Parasitology 2008; 24: 497-501.

4. Marcos LA, Terashima A, Gotuzzo E. Update on hepatobiliary flukes: fascioliasis, opisthorchiasis and clonorchiasis. Current Opinion in Infectious Diseases 2008; 21: 523.30.

5. Tang Z-L, Huang Y, Yu X-B. Current status and perspectives of Clonorchis sinensis and clonorchiasis: epidemiology, pathogenesis, omics, prevention and control. Infectious Diseases of Poverty [Internet]. 2016 Dec [cited 2017 May 22];5(1). Available from: http://idpjournal.biomedcentral.com/ articles/10.1186/s40249-016-0166-1

6. Sithithaworn P, Andrews RH, Van De N, Wongsaroj T, Sinuon M, Odermatt P, Y Nawa , et al. The current status of opisthorchiasis and clonorchiasis in the Mekong Basin. Parasitology International 2012; 61: 10-6.

7. Sayasone S, Meister I, Andrews JR, Odermatt P, Vonghachack Y, Xayavong S, Sangngam K, et al. Efficacy and safety of praziquantel against light infections of Opisthorchis viverrini: a randomised parallel single blind dose-ranging trial. Clin Infec Dis 2016; 7: 785.

8. Lovis L, Mak TK, Phongluxa K, Ayé Soukhathammavong P, Vonghachack Y, Keiser J, Vounatsou P, et al. Efficacy of Praziquantel against Schistosoma mekongi and Opisthorchis viverrini: A Randomized, Single-Blinded Dose-Comparison Trial. Sripa B, editor. PLoS Neglected Tropical Diseases 2012; 6: e1726.

9. Shirai T, Joong KD, Hakoi K, Thamavit W, Pairojkul C, Hoshiya T, Hasegawa R, et al. Promotion of rat hepatocarcinogenesis by praziquantel. Jpn J Cancer Res 1991; 82: 1085-8.

10. Kamsa-ard S, Luvira V, Pugkhem A, Luvira V, Thinkhamrop B, Suwanrungruang K, Bhuddhisawasdi V. Association between praziquantel treatment and cholangiocarcinoma: a hospital-based matched case–control study. BMC Cancer [Internet] 2015 Dec [cited 2017 May 21];15(1). Available from: http://bmccancer.biomedcentral.com/articles/10.1186/ s12885-015-1788-6

11. Saengsawang P, Promthet S, Bradshaw P. Infection with Opisthorchis viverrini and Use of Praziquantel among a Working-age Population in Northeast Thailand. Asian Pacific Journal of Cancer Prevention 2013; 14: 2963-6.

12. Aishima S, Oda Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. J Hepatobiliary Pancreat Sci 2015; 22: 94-100.

13. Luvira V, Pugkhem A, Bhudhisawasdi V, Pairojkul C, Sathitkarnmanee E, Luvira V, Kamsa-ard S. Long-term outcome of surgical resection for intraductal papillary neoplasm of the bile duct. J Gastroenterol Hepatol 2017; 32: 527-33.

14. Pinlaor S, Prakobwong S, Hiraku Y, Kaewsamut B, Dechakhamphu S, Boonmars T, Sithithaworn P, et al. Oxidative and nitrative stress in Opisthorchis viverrini–infected hamsters: an indirect effect after praziquantel treatment. The American Journal of Tropical Medicine and Hygiene 2008; 78: 564-73.

15. Chavengkun W, Kompor P, Norkaew J, Kujapun J, Pothipim M, Ponphimai S, Kaewpitoon S, et al. Raw Fish Consuming Behavior Related to Liver Fluke Infection among Populations at Risk of Cholangiocarcinoma in Nakhon Ratchasima Province, Thailand. Asian Pacific Journal of Cancer Prevention 2016; 17: 2761.

16. Saengsawang P, Promthet S, Bradshaw P. Reinfection by Opisthorchis Viverrini after Treatment with Praziquantel. Asian Pacific Journal of Cancer Prevention 2016; 17: 857- 62.

17. Chaimuangraj S, Thamavit W, Tsuda H, Moore MA. Experimental investigation of opisthorchiasis-associated cholangiocarcinoma induction in the Syrian hamster-pointers for control of the human disease. Asian Pacific Journal of Cancer Prevention 2003; 4: 87-94.

18. Wiwanitkit V, Surin Rajabhat University, Thailand. Cholangiocarcinoma and opisthorchiasis in Northeast Thailand: raw fish intake may not be the sole cause. Revista da Sociedade Brasileira de Medicina Tropical 2015; 48: 365.

19. Zen Y, Fujii T, Itatsu K, Nakamura K, Minato H, Kasashima S, Kurumaya S, et al. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 2006; 44: 1333-43.

20. Fujikura K, Fukumoto T, Ajiki T, et al. Comparative clinicopathological study of biliary intraductal papillary neoplasms and papillary cholangiocarcinomas. Histopathology 2016; 69: 950-61.

21. Jarnagin WR, Bowne W, Klimstra DS, Ben-Porat L, Roggin K, Cymes K, Fong Y, et al. Papillary Phenotype Confers Improved Survival After Resection of Hilar Cholangiocarcinoma. Ann Surg 2005; 241: 703-14.

22. Yeh C-N, Jan Y-Y, Yeh T-S, Hwang T-L, Chen M-F. Hepatic Resection of the Intraductal Papillary Type of Peripheral Cholangiocarcinoma. Ann Surg Oncol 2004; 11: 606-11.

23. Jan Y-Y, Yeh C-N, Yeh T-S, Chen T-C. Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol 2005; 11: 1779-84.

24. Nakanuma Y, Miyata T, Uchida T. Latest advances in the pathological understanding of cholangiocarcinomas. Expert Rev Gastroenterol Hepatol 2015; 22: 1-15.

25. Nakanuma Y. A novel approach to biliary tract pathology based on similarities to pancreatic counterparts: is the biliary tract an incomplete pancreas? Pathol Int 2010; 60: 419-29.